Amandeep Salhotra, MD, discusses preclinical findings that could support the addition of a BCL2 inhibitor to address acute or ...

Intestinal ischemia/reperfusion (I/R) injury is a common pathophysiological phenomenon that is widely present in various ...

Insights on the effect of Yanghe Decoction on osteosarcoma progression Osteosarcoma (OS) is a highly aggressive primary bone ...

Understanding how muscle deteriorates could help researchers extend the human health span. “When you ask most older adults ...

Researchers found that targeting cFLIP re-sensitized lymphoma cells to death signals in preclinical mouse models of DLBCL.

A research team at the University of Cologne's Center for Molecular Medicine Cologne (CMMC) has discovered that the protein ...

Scientists are developing therapies to eliminate chemotherapy-induced senescent 'zombie' cells, which may fuel inflammation and cancer relapse. These approaches include repurposing existing cancer ...

Chemotherapy kills cancer cells, but it also leaves behind something troubling: damaged cells that stop dividing yet refuse ...

After teasing a new regulatory process for personalized genetic medicines at the end of last year, the FDA today unveiled draft guidance for an approval pathway that could see custom CRISPR therapies, ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

The plausible mechanism pathway “could accelerate gene therapy/editing development,” analysts at William Blair said Thursday, while adding that additional clarity is needed. Individualized therapies ...

In a highly anticipated article, FDA officials Vinay Prasad, M.D., and Martin Makary, M.D., outlined a novel regulatory pathway that could trigger a seismic shift in how bespoke gene editing therapies ...